Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis
Arthritis & Rheumatism2004Vol. 50(5), pp. 1636–1641
Citations Over TimeTop 10% of 2004 papers
Juan D. Cañete, José L. Pablos, Raimón Sanmartí, Carme Mallofré, Sara Marsal, Joan Maymó, Jordi Gratacós, Jovita Mezquita, Cristóbal Mezquita, María C. Cid
Abstract
These results show consistent changes in several factors involved in angiogenesis regulation, in parallel with the clinical response to infliximab in patients with PsA. The pattern of reduced VEGF with increased Ang-2 suggests vascular regression as a potential mechanism underlying the antiangiogenic effect of infliximab.
Related Papers
- → Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases(2011)158 cited
- → Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease(2011)111 cited
- Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.(2006)
- → Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study(2011)41 cited
- [Management of failure of infliximab in inflammatory bowel disease].(2011)